Pitavastatin and Cardiovascular Disease in HIV

To the Editor: The findings of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), reported by Grinspoon et al. (Aug. 24 issue),1 put statins at the forefront on reducing the excess risk of atherosclerotic cardiovascular disease among persons with human immunodeficiency virus (HIV) in...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 389; no. 21; p. e46
Main Authors Olalla, Julián, Pombo, Marta
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 23.11.2023
Subjects
Acquired immune deficiency syndrome
AIDS
Arteriosclerosis
Atherosclerosis
Cardiovascular disease
Cardiovascular diseases
Conflicts of interest
Cost analysis
Disease prevention
Drug dosages
Drug therapy
HIV
Human immunodeficiency virus
Hypertension
Infections
Meta-analysis
Population
Risk factors
Statins
Systematic review
United Kingdom > UK
Australia
United States > US
Africa
Online AccessGet full text

Cover

More Information
Summary:To the Editor: The findings of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), reported by Grinspoon et al. (Aug. 24 issue),1 put statins at the forefront on reducing the excess risk of atherosclerotic cardiovascular disease among persons with human immunodeficiency virus (HIV) infection. We recently developed a model of atherosclerotic cardiovascular disease in persons with HIV infection.2 Applying the REPRIEVE results to our model shows that if pitavastatin is priced competitively with generic statins, expanded use among persons with HIV infection is likely to be cost-effective in the United States. However, this finding is sensitive to assumptions . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2311117